{"id":65178,"date":"2026-05-13T21:45:39","date_gmt":"2026-05-13T13:45:39","guid":{"rendered":"https:\/\/flcube.com\/?p=65178"},"modified":"2026-05-13T21:45:41","modified_gmt":"2026-05-13T13:45:41","slug":"changchun-genescience-receives-nmpa-approval-for-firsekibart-phase-iii-trial-in-gout-flare-prevention-during-urate-lowering-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65178","title":{"rendered":"Changchun GeneScience Receives NMPA Approval for Firsekibart Phase III Trial in Gout Flare Prevention During Urate-Lowering Therapy"},"content":{"rendered":"\n<p><strong>Changchun GeneScience Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/000661:SHE\">SHE: 000661<\/a>) announced it has received approval from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> to initiate a <strong>clinical study<\/strong> for its <strong>Category 1 drug firsekibart<\/strong> in reducing the risk of <strong>acute flares in gout patients<\/strong> during the initial phase of <strong>urate-lowering therapy (ULT)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-development-milestone\">Regulatory &amp; Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Changchun GeneScience Pharmaceutical Co., Ltd. (SHE: 000661)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Firsekibart (IL-1\u03b2 monoclonal antibody)<\/td><\/tr><tr><td><strong>Regulatory Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial authorization<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Prevention of acute gout flares during initial ULT phase<\/td><\/tr><tr><td><strong>Drug Classification<\/strong><\/td><td>Category 1 innovative drug<\/td><\/tr><tr><td><strong>Previous Approval<\/strong><\/td><td>July 2025 for acute gouty arthritis attacks<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-clinical-strategy\">Drug Profile &amp; Clinical Strategy<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-current-approved-indication\">Current Approved Indication<\/h3>\n\n\n\n<p>Firsekibart, an <strong>IL-1\u03b2 monoclonal antibody (mAb)<\/strong>, was initially approved in <strong>July 2025<\/strong> in China for:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Adult patients with <strong>acute gouty arthritis attacks<\/strong><\/li>\n\n\n\n<li>Patients <strong>contraindicated for, intolerant of, or unresponsive to NSAIDs and\/or colchicine<\/strong><\/li>\n\n\n\n<li>Patients <strong>unsuitable for repeated corticosteroid use<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-new-clinical-development-pathway\">New Clinical Development Pathway<\/h3>\n\n\n\n<p>The newly approved clinical study aims to expand firsekibart&#8217;s utility into <strong>prophylactic use<\/strong> during the critical initial phase of urate-lowering therapy, where up to <strong>70% of patients experience acute flares<\/strong> due to rapid changes in serum uric acid levels.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-access-amp-reimbursement-outlook\">Market Access &amp; Reimbursement Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NRDL Inclusion<\/strong>: Firsekibart has been included in the <strong>pre-communication list<\/strong> for <strong>2026 National Reimbursement Drug List (NRDL)<\/strong> negotiations<\/li>\n\n\n\n<li><strong>Expected Timeline<\/strong>: Formal NRDL negotiations anticipated later this year<\/li>\n\n\n\n<li><strong>Market Impact<\/strong>: NRDL inclusion would significantly improve patient access and drive volume adoption in China&#8217;s public healthcare system<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: As China&#8217;s first domestically developed IL-1\u03b2 mAb for gout, firsekibart represents a strategic asset in the growing biologics market for inflammatory conditions<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-changchun-genescience\">For Changchun GeneScience<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio expansion<\/strong>: Building on existing gout franchise with complementary indication<\/li>\n\n\n\n<li><strong>Revenue diversification<\/strong>: Moving from acute treatment to chronic management paradigm<\/li>\n\n\n\n<li><strong>Biologics leadership<\/strong>: Strengthening position in China&#8217;s domestic monoclonal antibody development landscape<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Gout prevalence<\/strong>: Estimated <strong>40-60 million gout patients<\/strong> in China, with growing incidence due to dietary and lifestyle factors<\/li>\n\n\n\n<li><strong>ULT adoption<\/strong>: Increasing use of urate-lowering therapies creates substantial prophylactic market opportunity<\/li>\n\n\n\n<li><strong>Treatment gap<\/strong>: Limited options for flare prevention during ULT initiation represent significant unmet medical need<\/li>\n<\/ul>\n\n\n\n<p>The expanded clinical development program positions firsekibart as a comprehensive gout management solution, potentially capturing both acute treatment and prophylactic market segments.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and market access for firsekibart. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u4f0f\u6b23\u5947\u62dc\u5355\u6297\u6ce8\u5c04\u6db2\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u4f0f\u6b23\u5947\u62dc\u5355\u6297\u6ce8\u5c04\u6db2\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-b13e6d3d-a592-43bc-a730-54999b0d052b\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u4f0f\u6b23\u5947\u62dc\u5355\u6297\u6ce8\u5c04\u6db2\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\">\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u4f0f\u6b23\u5947\u62dc\u5355\u6297\u6ce8\u5c04\u6db2\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u4f0f\u6b23\u5947\u62dc\u5355\u6297\u6ce8\u5c04\u6db2\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b13e6d3d-a592-43bc-a730-54999b0d052b\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Changchun GeneScience Pharmaceutical Co., Ltd. (SHE: 000661) announced it has received approval from China&#8217;s National&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,358,1171],"class_list":["post-65178","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-genescience-pharmaceutical","tag-she-000661"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Changchun GeneScience Receives NMPA Approval for Firsekibart Phase III Trial in Gout Flare Prevention During Urate-Lowering Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Changchun GeneScience Pharmaceutical Co., Ltd. (SHE: 000661) announced it has received approval from China&#039;s National Medical Products Administration (NMPA) to initiate a clinical study for its Category 1 drug firsekibart in reducing the risk of acute flares in gout patients during the initial phase of urate-lowering therapy (ULT).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65178\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Changchun GeneScience Receives NMPA Approval for Firsekibart Phase III Trial in Gout Flare Prevention During Urate-Lowering Therapy\" \/>\n<meta property=\"og:description\" content=\"Changchun GeneScience Pharmaceutical Co., Ltd. (SHE: 000661) announced it has received approval from China&#039;s National Medical Products Administration (NMPA) to initiate a clinical study for its Category 1 drug firsekibart in reducing the risk of acute flares in gout patients during the initial phase of urate-lowering therapy (ULT).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65178\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-13T13:45:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-13T13:45:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65178#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65178\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Changchun GeneScience Receives NMPA Approval for Firsekibart Phase III Trial in Gout Flare Prevention During Urate-Lowering Therapy\",\"datePublished\":\"2026-05-13T13:45:39+00:00\",\"dateModified\":\"2026-05-13T13:45:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65178\"},\"wordCount\":423,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"GeneScience Pharmaceutical\",\"SHE: 000661\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65178#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65178\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65178\",\"name\":\"Changchun GeneScience Receives NMPA Approval for Firsekibart Phase III Trial in Gout Flare Prevention During Urate-Lowering Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-13T13:45:39+00:00\",\"dateModified\":\"2026-05-13T13:45:41+00:00\",\"description\":\"Changchun GeneScience Pharmaceutical Co., Ltd. (SHE: 000661) announced it has received approval from China's National Medical Products Administration (NMPA) to initiate a clinical study for its Category 1 drug firsekibart in reducing the risk of acute flares in gout patients during the initial phase of urate-lowering therapy (ULT).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65178#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65178\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65178#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Changchun GeneScience Receives NMPA Approval for Firsekibart Phase III Trial in Gout Flare Prevention During Urate-Lowering Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Changchun GeneScience Receives NMPA Approval for Firsekibart Phase III Trial in Gout Flare Prevention During Urate-Lowering Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Changchun GeneScience Pharmaceutical Co., Ltd. (SHE: 000661) announced it has received approval from China's National Medical Products Administration (NMPA) to initiate a clinical study for its Category 1 drug firsekibart in reducing the risk of acute flares in gout patients during the initial phase of urate-lowering therapy (ULT).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65178","og_locale":"en_US","og_type":"article","og_title":"Changchun GeneScience Receives NMPA Approval for Firsekibart Phase III Trial in Gout Flare Prevention During Urate-Lowering Therapy","og_description":"Changchun GeneScience Pharmaceutical Co., Ltd. (SHE: 000661) announced it has received approval from China's National Medical Products Administration (NMPA) to initiate a clinical study for its Category 1 drug firsekibart in reducing the risk of acute flares in gout patients during the initial phase of urate-lowering therapy (ULT).","og_url":"https:\/\/flcube.com\/?p=65178","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-13T13:45:39+00:00","article_modified_time":"2026-05-13T13:45:41+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65178#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65178"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Changchun GeneScience Receives NMPA Approval for Firsekibart Phase III Trial in Gout Flare Prevention During Urate-Lowering Therapy","datePublished":"2026-05-13T13:45:39+00:00","dateModified":"2026-05-13T13:45:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65178"},"wordCount":423,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","GeneScience Pharmaceutical","SHE: 000661"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65178#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65178","url":"https:\/\/flcube.com\/?p=65178","name":"Changchun GeneScience Receives NMPA Approval for Firsekibart Phase III Trial in Gout Flare Prevention During Urate-Lowering Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-13T13:45:39+00:00","dateModified":"2026-05-13T13:45:41+00:00","description":"Changchun GeneScience Pharmaceutical Co., Ltd. (SHE: 000661) announced it has received approval from China's National Medical Products Administration (NMPA) to initiate a clinical study for its Category 1 drug firsekibart in reducing the risk of acute flares in gout patients during the initial phase of urate-lowering therapy (ULT).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65178#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65178"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65178#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Changchun GeneScience Receives NMPA Approval for Firsekibart Phase III Trial in Gout Flare Prevention During Urate-Lowering Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65178","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65178"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65178\/revisions"}],"predecessor-version":[{"id":65180,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65178\/revisions\/65180"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65178"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65178"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65178"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}